A Phase 3 interventional study of Romosozumab and Placebo in Osteoporosis in Men, sponsored by Amgen. Completed at 34 sites in 10 countries. Open to male participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-05-28.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.
Among the 20 studies testing romosozumab in Osteoporosis, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 6th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
University of Aarhus · Sites in Denmark
Ages 50+ · Women only
Sahlgrenska University Hospital · Sites in Sweden
Ages 60+ · Women only
Tuen Mun Hospital · Sites in Hong Kong
Ages 18+
Marmara University · Sites in Turkey
Ages 55–85 · Women only
By country, each count listing its studies:
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years to 90 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2014.
This study's enrollment of 245 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 80 across the 20 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 16th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2014, is one of 18 in phase 3, and was the 25th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
3 of the studies testing romosozumab in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07757373Tuen Mun HospitalRomosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing romosozumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The study is designed to evaluate if treatment with romosozumab once a month for 12 months compared with placebo is effective in increasing bone mineral density (BMD) at the lumbar spine. Additionally, the study will assess the effect of treatment with romosozumab for 12 months compared with placebo on BMD at the femoral neck and total hip.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
Biological: Romosozumab
Participants received placebo subcutaneous injections once a month for 12 months.
Drug: Placebo
Administered by subcutaneous injection once a month.
Also known as: AMG 785, EVENITY™
Administered by subcutaneous injection once a month.
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12
Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 12
Percent Change From Baseline in BMD at the Total Hip at Month 12
Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 12
Percent Change From Baseline in BMD at the Femoral Neck at Month 12
Femoral neck bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 12
Percent Change From Baseline in Lumbar Spine BMD at Month 6
Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 6
Percent Change From Baseline in BMD at the Total Hip at Month 6
Bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 6
Percent Change From Baseline in BMD at the Femoral Neck at Month 6
Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 6
This study was conducted at 31 centers in Europe, North America, Latin America, and Japan. Participants were enrolled from 16 June 2014 to 27 January 2015.
| Milestone | Placebo | Romosozumab 210 mg |
|---|---|---|
| Started | 82 | 163 |
| Received treatment | 81 | 163 |
| Completed | 78 | 148 |
| Not completed | 4 | 15 |
| Withdrew: Withdrawal by subject | 1 | 9 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Protocol-specified criteria | 0 | 2 |
Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12 | 1.2 ± 0.5 | 12.1 ± 0.5 |
Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in BMD at the Total Hip at Month 12 | -0.5 ± 0.3 | 2.5 ± 0.2 |
Femoral neck bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in BMD at the Femoral Neck at Month 12 | -0.2 ± 0.4 | 2.2 ± 0.4 |
Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine BMD at Month 6 | 0.3 ± 0.4 | 9.0 ± 0.4 |
Bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in BMD at the Total Hip at Month 6 | 0.2 ± 0.2 | 1.6 ± 0.2 |
Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in BMD at the Femoral Neck at Month 6 | 0.0 ± 0.4 | 1.2 ± 0.3 |
Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 10/81 (12.3%) | 41/81 (50.6%) |
| Romosozumab 210 mg | — | 23/163 (14.1%) | 74/163 (45.4%) |
| Event | Placebo | Romosozumab 210 mg |
|---|---|---|
| Atrial fibrillationCardiac disorders | 1/81 | 0/163 |
| Atrial flutterCardiac disorders | 1/81 | 1/163 |
| Cardiac valve diseaseCardiac disorders | 1/81 | 0/163 |
| Abdominal painGastrointestinal disorders | 1/81 | 0/163 |
| Abdominal pain upperGastrointestinal disorders | 1/81 | 0/163 |
| Intra-abdominal haemorrhageGastrointestinal disorders | 1/81 | 0/163 |
| DeathGeneral disorders | 1/81 | 1/163 |
| Non-cardiac chest painGeneral disorders | 1/81 | 1/163 |
| Atypical pneumoniaInfections and infestations | 1/81 | 0/163 |
| Pneumonia bacterialInfections and infestations | 1/81 | 0/163 |
| Event | Placebo | Romosozumab 210 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 22/81 | 35/163 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/81 | 10/163 |
| Back painMusculoskeletal and connective tissue disorders | 4/81 | 15/163 |
| HypertensionVascular disorders | 5/81 | 14/163 |
| Procedural painInjury, poisoning and procedural complications | 6/81 | 8/163 |
| HeadacheNervous system disorders | 6/81 | 10/163 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 5/81 | 3/163 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/81 | 4/163 |
| ConstipationGastrointestinal disorders | 1/81 | 9/163 |
| Age, Continuous(years) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | 71.5 ± 6.9 | 72.4 ± 7.4 | 72.1 ± 7.3 |
| Age, Customized(Participants) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| 18 - 64 years | 11 | 31 | 42 |
| 65 - 74 years | 42 | 62 | 104 |
| 75 years and over | 29 | 70 | 99 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 82 | 163 | 245 |
| Race(Participants) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| White | 60 | 120 | 180 |
| Asian | 9 | 18 | 27 |
| Black or African American | 0 | 1 | 1 |
| Other | 13 | 23 | 36 |
| Multiple | 0 | 1 | 1 |
| Geographic Region(Participants) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Europe | 54 | 108 | 162 |
| Japan | 9 | 18 | 27 |
| Latin America | 12 | 23 | 35 |
| North America | 7 | 14 | 21 |
| Lumbar Spine Bone Mineral Density T-score(T-score) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | -2.33 ± 1.41 | -2.22 ± 1.19 | -2.26 ± 1.27 |
| Total Hip BMD T-score(T-score) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | -1.92 ± 0.65 | -1.92 ± 0.59 | -1.92 ± 0.61 |
| Femoral Neck BMD T-score(T-score) | Placebo | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | -2.30 ± 0.52 | -2.34 ± 0.52 | -2.33 ± 0.52 |
Ran from Jun 2014 to primary completion in Feb 2016, 19 months.
Results were first posted in May 2019, 3 years 3 months after primary completion. A results delay was requested in Sep 2016.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 19 months is below that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab